Induction of a program gene expression during osteoblast differentiation with strontium ranelate

Biochemical and Biophysical Research Communications

Volumn 355, Issue 2, 2007, Pages 307-311

  Zhu, Ling Ling ^a   Zaidi, Samir ^a   Peng, Yuanzhen ^a   Zhou, Hang ^a   Moonga, Baljit S ^a   Blesius, Alexia ^b   Dupin Roger, Isabelle ^b   Zaidi, Mone ^a   Sun, Li ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Osteoblast; Osteoporosis; Strontium ranelate

Indexed keywords

BONE SIALOPROTEIN; OSTEOCALCIN; STRONTIUM RANELATE;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL SPECIFICITY; DRUG ACTIVITY; DRUG INDICATION; GENE; GENE EXPRESSION; GENE INDUCTION; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; RUNX2 GENE;

ANIMALS; CELL DIFFERENTIATION; GENE EXPRESSION; MICE; MICE, INBRED C57BL; ORGANOMETALLIC COMPOUNDS; OSTEOBLASTS; POLYMERASE CHAIN REACTION; THIOPHENES;

EID: 33847162089     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.01.120     Document Type: Article

References (20)

1. Marie P.J. Strontium ranelate: a novel mode of action optimizing bone formation. Osteoporosis Int. 16 (2005) S7-S10
2. Pors Neilson S. The biological role of strontium. Bone 35 (2004) 583-588
3. Ammann P. Strontium ranelate: a novel mode of action leading to renewed bone quality. Osteoporosis Int. 16 (2005) S11-S15
4. Baron R., and Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur. J. Pharmacol. 450 (2002) 11-17
5. Barbara A., Delannoy P., Denis B.G., and Marie P.J. Normal matrix mineralization induced by strontium ranelate in MC3T3-E1 osteogenic cells. Metabolism 53 (2004) 532-537
6. Reginster J.Y., Seeman E., De Vernejoul M.C., Adami S., Compston J., Phenekos C., Devogelaer J.P., Curiel M.D., Sawicki A., Goemaere S., Sorensen O.H., Felsenberg D., and Meunier P.J. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 90 (2005) 2816-2822
7. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., Cannata J., Balogh A., Lemmel E.M., Pors-Nielsen S., Rizzoli R., Genant H.K., and Reginster J.Y. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350 (2004) 459-468
8. Bain S., Shen V., Hara P., and Dupin-Roger I. Long-term treatment with strontium ranelate increases histomorphometric indices of bone formation in ovariectomized rats. J. Bone Miner. Res. 33 (2004) 115-123
9. Marie P.J., Hott M., Modrowski D., De Pollak C., Guillemain J., Deloffre P., and Tsouderor Y. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J. Bone Miner. Res. 8 (1993) 607-615
10. Hott M., Deloffre P., Tsouderos Y., and Marie P.J. S12911-2 reduces bone loss induced by short-term immobilization in rats. Bone 33 (2003) 115-123
11. Buehler J., Chappuis P., Saffar J.L., Tsouderos Y., and Vignery A. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 29 (2001) 176-179
12. Canalis E., Hott M., Deloffre P., Tsouderos Y., and Marie P.J. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 18 (1996) 517-523
13. Takahashi N., Sasaki T., Tsouderos Y., and Suda T. S12911-2 inhibits osteoclastic bone resorption in vitro. J. Bone Miner. Res. 18 (2003) 1082-1087
14. Verberckmoes S.C., De Broe M.E., and D'Haese P.C. Dose-dependent effects of strontium on osteoblast function and mineralization. Kidney Int. 64 (2003) 534-543
15. Karsenty G., Ducy P., Starbuck M., Priemel M., Shen J., Geoffroy V., and Amling M. Cbfa1 as a regulator of osteoblast differentiation and function. Bone 25 (1999) 107-108
16. Karsenty G. Transcriptional regulation of osteoblast differentiation during development. Front Biosci. 3 (2003) 834-837
17. Abe E., Marians R.C., Yu W., Wu X.B., Ando T., Li Y., Iqbal J., Eldiery L., Rajendren G., Blair H.C., Davies T.F., and Zaidi M. TSH is a negative regulator of skeletal remodeling. Cell 115 (2003) 151-162
18. Zhu L.L., Zaidi S., Moonga B.S., Troen B.R., and Sun L L. RANK-L induces the expression of NFATc1, but not of NFkappaB subunits during osteoclast formation. Biochem. Biophys. Res. Commun. 326 (2005) 131-135
19. Brown E.M. Is the calcium receptor a molecular target for the actions of strontium on bone?. Osteoporosis Int. 14 (2003) S25-S34
20. Zaidi M., Kerby J., Huang C.L., Alam T., Rathod H., Chambers T.J., and Moonga B.S. Divalent cations mimic the inhibitory effect of extracellular ionised calcium on bone resorption by isolated rat osteoclasts: further evidence for a "calcium receptor". J. Cell Physiol. 149 (1991) 422-427